GlobeNewswire: Radius Health Inc. Contains the last 10 of 278 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:51:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/08/15/2498274/0/en/Gurnet-Point-Capital-and-Patient-Square-Capital-Complete-Their-Acquisition-of-Radius-Health-Inc.html?f=22&fvtc=4&fvtv=22059Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.2022-08-15T13:00:00Z<![CDATA[CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.]]>https://www.globenewswire.com/news-release/2022/07/07/2476330/0/en/Radius-Health-Publishes-Investor-Presentation-Outlining-Company-s-Progress-and-Board-Process-Resulting-in-Agreement-to-be-Acquired-at-Significant-Premium.html?f=22&fvtc=4&fvtv=22059Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium2022-07-07T22:30:00Z<![CDATA[BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/.]]>https://www.globenewswire.com/news-release/2022/07/07/2475806/0/en/Radius-Announces-First-Patient-Randomized-in-the-RAD011-Pivotal-Trial-for-Prader-Willi-Syndrome.html?f=22&fvtc=4&fvtv=22059Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome2022-07-07T12:00:00Z<![CDATA[BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the first patient has been randomized in the Phase 2/3 pivotal study, SCOUT-015, to evaluate RAD011, a synthetic cannabidiol oral solution, for the treatment of hyperphagia and related neuro-behavioral symptoms in Prader-Willi Syndrome (PWS), a rare neuro-endocrine orphan disease which effects between approximately 20,000 and 30,000 patients in the US.]]>https://www.globenewswire.com/news-release/2022/06/23/2468089/0/en/Radius-Health-Announces-Agreement-to-be-Acquired-by-Gurnet-Point-Capital-and-Patient-Square-Capital.html?f=22&fvtc=4&fvtv=22059Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital2022-06-23T13:15:00Z<![CDATA[BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has entered into a definitive agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR (Contingent Value Right). Debt financing for this transaction will be provided by OrbiMed Advisors, LLC.]]>https://www.globenewswire.com/news-release/2022/06/22/2467521/0/en/Menarini-Group-and-Radius-Health-Submit-New-Drug-Application-to-the-U-S-FDA-for-Elacestrant.html?f=22&fvtc=4&fvtv=22059Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant2022-06-22T20:30:00Z<![CDATA[FLORENCE, Italy and BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.]]>https://www.globenewswire.com/news-release/2022/06/08/2458699/0/en/Radius-Health-Expands-Non-US-Market-Footprint-for-TYMLOS.html?f=22&fvtc=4&fvtv=22059Radius Health Expands Non-US Market Footprint for TYMLOS2022-06-08T12:00:00Z<![CDATA[BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection.]]>https://www.globenewswire.com/news-release/2022/06/06/2456838/0/en/Menarini-Group-and-Radius-Health-Inc-present-a-subgroup-analysis-from-the-elacestrant-pivotal-phase-3-EMERALD-clinical-trial-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-.html?f=22&fvtc=4&fvtv=22059Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting2022-06-06T13:00:00Z<![CDATA[Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC)]]>https://www.globenewswire.com/news-release/2022/06/06/2456600/0/en/Radius-Files-Definitive-Proxy-and-Mails-Letter-to-Stockholders.html?f=22&fvtc=4&fvtv=22059Radius Files Definitive Proxy and Mails Letter to Stockholders2022-06-06T11:30:00Z<![CDATA[Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card]]>https://www.globenewswire.com/news-release/2022/06/01/2454734/0/en/Radius-Health-Update-on-Abaloparatide-Transdermal-System.html?f=22&fvtc=4&fvtv=22059Radius Health Update on Abaloparatide Transdermal System2022-06-01T20:15:00Z<![CDATA[BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the abaloparatide transdermal system (abalo-TDS) development program.]]>https://www.globenewswire.com/news-release/2022/05/20/2447727/0/en/Radius-Adds-Industry-Veterans-Jennifer-A-Jarrett-and-Susan-Vissers-Lisa-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=22059Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors2022-05-20T13:00:00Z<![CDATA[Further Expands Board’s Expertise and Gender Diversity]]>